A predictive model for residual disease after (chemo) radiotherapy in oropharyngeal carcinoma: Combined radiological and clinical evaluation of tumor.

Slides:



Advertisements
Similar presentations
2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.
Advertisements

Differential drug responses of circulating tumor cells within patient blood Andrew D. Hughes, Jocelyn R. Marshall, Eric Keller, John D. Powderly, Bryan.
Combined PTEN Mutation and Protein Expression Associate with Overall and Disease- Free Survival of Glioblastoma Patients Jie Xu, Zhaoli Li, Jilin Wang,
Pathologic response after neoadjuvant chemotherapy predicts locoregional control in patients with triple negative breast cancer  Victor E. Chen, BS, Erin.
18Fluorodeoxyglucose PET Is Prognostic of Progression-Free and Overall Survival in Locally Advanced Pancreas Cancer Treated With Stereotactic Radiotherapy 
Long-term follow-up of patients with locally advanced non-small cell lung cancer receiving concurrent hypofractionated chemoradiotherapy with or without.
Timing of Radiation Therapy and Chemotherapy After Breast-Conserving Surgery for Node-Positive Breast Cancer: Long-Term Results From International Breast.
Development of a multivariable normal tissue complication probability (NTCP) model for tube feeding dependence after curative radiotherapy/chemo-radiotherapy.
Volume 63, Pages 1-9 (December 2016)
Swallowing sparing intensity modulated radiotherapy (SW-IMRT) in head and neck cancer: Clinical validation according to the model-based approach  Miranda.
The effect of perioperative chemotherapy for patients with an adenocarcinoma of the gastroesophageal junction: A propensity score matched analysis  K.
Cardiac comorbidity is an independent risk factor for radiation-induced lung toxicity in lung cancer patients  Georgi Nalbantov, Bas Kietselaer, Katrien.
High-Dose-Rate Brachytherapy Boost for Prostate Cancer: Comparison of Two Different Fractionation Schemes  Tania Kaprealian, M.D., Vivian Weinberg, Ph.D.,
Building better therapy for children with acute lymphoblastic leukemia
Khaled M. Madbouly, Abdrabou N. Mashhour, Waleed Omar 
Hormone Therapy for Prostate Cancer: Exploring Current Controversies
SYSTEMS-2: A randomised phase II study of radiotherapy dose escalation for pain control in malignant pleural mesothelioma  M. Ashton, N. O'Rourke, N.
Clinical and Translational Radiation Oncology
Volume 67, Issue 6, Pages (June 2015)
Volume 150, Issue 3, Pages (September 2018)
Pain in cancer survivors; filling in the gaps
Volume 151, Issue 1, Pages (October 2018)
Translating the Latest and Greatest Advances in PAH Into Clinical Practice.
How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development  R. Bax  Clinical Microbiology.
Patient-reported symptoms and performance status before palliative radiotherapy in geriatric cancer patients (octogenarians)  Carsten Nieder, Thomas A.
Surgery vs. primary radiotherapy in early-stage oropharyngeal cancer
Role of radiotherapy in extracranial metastatic malignant melanoma in the modern era  Ryan S. Youland, Miran L. Blanchard, Roxanna Dronca, Lisa Kottschade,
Michiel van den Bosch, Michel Öllers, Bart Reymen, Wouter van Elmpt 
Clinical and Translational Radiation Oncology
Sofie Arens, Jan Verhaegen, Ludo Verbist 
The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.
Repke J Snijder, Aart Brutel de la Rivière, Hans J. J Elbers, Jules M
Follow up results of a prospective study to evaluate the impact of FDG-PET on CT- based radiotherapy treatment planning for oesophageal cancer  Sweet Ping.
Survival and failure types after radiation therapy of vulvar cancer
A neuropathic pain component as a predictor of improvement in pain interference after radiotherapy for painful tumors: A secondary analysis of a prospective.
A predictive model for residual disease after (chemo) radiotherapy in oropharyngeal carcinoma: Combined radiological and clinical evaluation of tumor.
Evaluating the prevalence and predictive factors of vasomotor and psychological symptoms in prostate cancer patients receiving hormonal therapy: Results.
Age-not Charlson Co-morbidity Index-predicts for mortality after stereotactic ablative radiotherapy for medically inoperable stage I non-small cell lung.
Phase II study of induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil followed by radioimmunotherapy with cetuximab and intensity-modulated.
A. A. Klein, T. Collier, J. Yeates, L. F. Miles, S. N. Fletcher, C
Impact of waiting time on nodal staging in head and neck squamous-cell carcinoma treated with radical intensity modulated radiotherapy  Cédric Chevalier,
Cone-Beam CT-based position verification for oesophageal cancer: Evaluation of registration methods and anatomical changes during radiotherapy  A. van.
Study of diffusion weighted MRI as a predictive biomarker of response during radiotherapy for high and intermediate risk squamous cell cancer of the oropharynx:
Jean-Emmanuel Bibault, Ingeborg Tinhofer 
Magnetic Resonance-based Response Assessment and Dose Adaptation in Human Papilloma Virus Positive Tumors of the Oropharynx treated with Radiotherapy.
What is the impact of diabetes mellitus on radiation induced acute proctitis after radical radiotherapy for adenocarcinoma prostate? A prospective longitudinal.
A propensity analysis comparing definitive chemo-radiotherapy for muscle-invasive squamous cell carcinoma of the bladder vs. urothelial carcinoma of the.
Clinical and radiobiological evaluation of a method for planning target volume generation dependent on organ-at-risk exclusions in magnetic resonance.
Prognostic impact of leukocyte counts before and during radiotherapy for oropharyngeal cancer  Garrett L. Jensen, Pierre Blanchard, G. Brandon Gunn, Adam.
Arlene Chan, Marc Buyse, Bin Yao  The Lancet Oncology 
Prognostic Factors in Non–Muscle-Invasive Bladder Tumors
The posterior cerebellum, a new organ at risk?
E. Tacconelli  Clinical Microbiology and Infection 
Differences in patterns of care and outcomes between grade II and grade III molecularly defined 1p19q co-deleted gliomas  Debra Nana Yeboa, James B. Yu,
J.J. Keller, M.-C. Tsai, C.-C. Lin, Y.-C. Lin, H.-C. Lin 
Outcome of prosthetic knee-associated infection: evaluation of 40 consecutive episodes at a single centre  R.R. Laffer, P. Graber, P.E. Ochsner, W. Zimmerli 
Plasma proteins as prognostic biomarkers in radiotherapy treated head and neck cancer patients  Line Brøndum, Jesper Grau Eriksen, Brita Singers Sørensen,
Pulmonary Resection for Metastases from Colorectal Cancer
Olga Vornicova, MD, Gil Bar-Sela, MD  JAAD Case Reports 
Oncoforum Urology: Prostate Cancer 2008 at a Glance
Differential impacts of modes of anaesthesia on the risk of stroke among preeclamptic women who undergo Caesarean delivery: a population-based study 
Technical Innovations and Patient Support in Radiation Oncology
Prostate-specific membrane antigen positron emission tomography/computed tomography as a potential tool to assess and guide salivary gland irradiation 
Radiation dose mapping and anastomotic complications after trimodality therapy for esophageal cancers  Andrew Bang, Joel A. Broomfield, Jessica Chan,
Impact of Tumor Size on Local Control and Pneumonitis After Stereotactic Body Radiation Therapy for Lung Tumors  Sean M. Parker, BS, R. Alfredo Siochi,
Patterns of practice in palliative radiotherapy for bleeding tumours in the Netherlands; a survey study among radiation oncologists  Jennifer Strijbos,
Stage I Non-small Cell Lung Cancer: Results for Surgery in a Patterns-of-Care Study in Sydney and for High-Dose Concurrent End-Phase Boost Accelerated.
Although non-stroke outcomes are more common, stroke risk scores can be used for prediction in patients with atrial fibrillation  Finlay A. McAlister,
Clinical and Translational Radiation Oncology
Systematic review of methodology used in clinical studies evaluating the benefits of proton beam therapy  Mercy Ofuya, Lucy McParland, Louise Murray,
Presentation transcript:

A predictive model for residual disease after (chemo) radiotherapy in oropharyngeal carcinoma: Combined radiological and clinical evaluation of tumor response  Zeno A.R. Gouw, Bas Jasperse, Jan-Jakob Sonke, Wilma D. Heemsbergen, Arash Navran, Olga Hamming-Vrieze, Jan Paul de Boer, Michiel W.M. van den Brekel, Abrahim Al-Mamgani  Clinical and Translational Radiation Oncology  Volume 6, Pages 1-6 (October 2017) DOI: 10.1016/j.ctro.2017.07.002 Copyright © 2017 The Authors Terms and Conditions

Fig. 1 Local failure free survival for patients with Ojiri-score 0+1 vs patients with Ojiri-score 2a+b. The dotted line represents the RD threshold of 6months. All LF’s before this threshold are categorized as RD. Twenty out of 188 patients with Ojiri 0+1 had LF (10.6%), of which 4 were a RD. Eleven out of 46 patients with Ojiri 2a+b (23.9%) had LF and 8 out of 11 LF’s were a RD. Patients with Ojiri 0+1 had a significant better local failure free survival (p=0.013). Abbreviations: RD=residual disease, LF=local failure. Clinical and Translational Radiation Oncology 2017 6, 1-6DOI: (10.1016/j.ctro.2017.07.002) Copyright © 2017 The Authors Terms and Conditions

Fig. 2 Local failure free survival for patients with CS vs patients without CS. The dotted line represents the RD threshold of 6months. All LF’s before this threshold are categorized as RD. Of the 163 patients without CS, 8 had a LF (4.9%) and none of them were a RD. For patients with CS, 23 out of 71 had a LF (32.4%) of which 12 were a RD. Patients without CS had a significant better local failure free survival (p<1e−8). Abbreviations: RD=residual disease, LF=local failure. Clinical and Translational Radiation Oncology 2017 6, 1-6DOI: (10.1016/j.ctro.2017.07.002) Copyright © 2017 The Authors Terms and Conditions

Fig. 3 Risk stratification based on Ojiri-score and CS. Three risk groups are created with 0% RD for low risk-patients, 8.2% RD in intermediate-risk and 23.5% RD in the high-risk group. We propose to further differentiate patients with- and without RD in the intermediate-risk group, Referring patients with CMR to clinical follow up and PMR to EUA with biopsies. Abbreviations: RD=residual disease, CS=clinical suspicion, N=number of patients, MR=metabolic response, EUA=examination under anesthesia. Clinical and Translational Radiation Oncology 2017 6, 1-6DOI: (10.1016/j.ctro.2017.07.002) Copyright © 2017 The Authors Terms and Conditions

Supplementary Fig. 1 Local failure free survival without CS vs. with CS regarding only Ojiri-score 0+1 patients. The dotted line represents the RD threshold of 6months. All LF’s before this threshold are categorized as RD. Of the 151 patients without CS, 8 had a LF (5.3%) and none of them where a RD. For patients with CS, 12 out of 37 had a LF (32.4%) of which 4 where a RD. Patients without CS had a significant better local failure free survival (p<1e-6). Abbreviations: RD=residual disease, LF=local failure. Clinical and Translational Radiation Oncology 2017 6, 1-6DOI: (10.1016/j.ctro.2017.07.002) Copyright © 2017 The Authors Terms and Conditions

Supplementary Fig. 2 Local failure free survival without CS vs. with CS regarding only Ojiri-score 2a+b patients. The dotted line represents the RD threshold of 6months. All LF’s before this threshold are categorized as RD. Of the 12 patients without CS none had a LF. For patients with CS, 11 out of 34 had a LF (32.4%) of which 8 where a RD. Patients without CS had a significant better local failure free survival (p=0.034). Abbreviations: RD=residual disease, LF=local failure. Clinical and Translational Radiation Oncology 2017 6, 1-6DOI: (10.1016/j.ctro.2017.07.002) Copyright © 2017 The Authors Terms and Conditions